CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Jan. 4, 2021--
Repare Therapeutics, Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics, today announced that Lloyd M. Segal, President and Chief Executive Officer, will present at two upcoming virtual investor conferences:
H.C. Wainwright Virtual BioConnect Conference
Date: Monday, January 11 – Thursday, January 14
39th Annual J.P. Morgan Healthcare Conference
Date: Thursday, January 14
Time: 8:20 a.m. Eastern Time
The H.C. Wainwright presentation will be pre-recorded and available on Monday, January 11, 2021, at 6:00 a.m. Eastern Time in the Investor section of the Company’s website at https://ir.reparerx.com/news-and-events/events. A live webcast of the J.P. Morgan presentation will be available in the same section of the website. A replay of both webcasts will be archived for 30 days following each presentation date.
About Repare Therapeutics, Inc.
Repare Therapeutics is a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics. The Company utilizes its genome-wide, CRISPR-enabled SNIPRx® platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. The Company’s pipeline includes its lead product candidate RP-3500, a potential leading ATR inhibitor, as well as CCNE1-SL inhibitor and Polθ inhibitor programs. For more information, please visit reparerx.com.
SNIPRx® is a registered trademark of Repare Therapeutics, Inc.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210104005027/en/
Chief Financial Officer
Repare Therapeutics, Inc.
Source: Repare Therapeutics, Inc.